GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Sloan Ratio %

iCo Therapeutics (iCo Therapeutics) Sloan Ratio % : 0.00% (As of Mar. 2021)


View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

iCo Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2021 was 0.00%.

As of Mar. 2021, iCo Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


iCo Therapeutics Sloan Ratio % Historical Data

The historical data trend for iCo Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Sloan Ratio % Chart

iCo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.26 - -335.61 20.81 -

iCo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of iCo Therapeutics's Sloan Ratio %

For the Biotechnology subindustry, iCo Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iCo Therapeutics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's Sloan Ratio % falls into.



iCo Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

iCo Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2020 )-Cash Flow from Operations (A: Dec. 2020 )
-Cash Flow from Investing (A: Dec. 2020 ))/Total Assets (A: Dec. 2020 )
=(-1.162--0.707
-0)/0.426
=-106.81%

iCo Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2021 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2021 )
=(-1.244--0.079
-0.002)/1.738
=-67.15%

iCo Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2021 was -0.235 (Jun. 2020 ) + -0.146 (Sep. 2020 ) + -0.249 (Dec. 2020 ) + -0.614 (Mar. 2021 ) = $-1.24 Mil.
iCo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2021 was -0.071 (Jun. 2020 ) + -0.146 (Sep. 2020 ) + -0.077 (Dec. 2020 ) + 0.215 (Mar. 2021 ) = $-0.08 Mil.
iCo Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2021 was 0 (Jun. 2020 ) + 0.002 (Sep. 2020 ) + 0 (Dec. 2020 ) + 0 (Mar. 2021 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iCo Therapeutics  (GREY:ICOTF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2021, iCo Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


iCo Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


iCo Therapeutics (iCo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines